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CalciumAllergic asthma is a chronic inﬂammatory airway disease with increasing prevalence around the world. Current
asthma therapy includes drugs that usually cause signiﬁcant side effects, justifying the search for new anti-
asthmatic drugs. Curine is a bisbenzylisoquinoline alkaloid that modulates calcium inﬂux in many cell types;
however, its anti-allergic and putative toxic effects remain to be elucidated. Our aimwas to investigate the effects
of curine on eosinophil activation and airway hyper-responsiveness (AHR) and to characterize its potential toxic
effects.Weused amousemodel of allergic asthma induced by sensitization and challengewith ovalbumin (OVA)
to evaluate the anti-allergic effects of oral treatment with curine. The oral administration of curine signiﬁcantly
inhibited eosinophilic inﬂammation, eosinophil lipid body formation and AHR in animals challenged with OVA
compared with animals in the untreated group. The curine treatment also reduced eotaxin and IL-13 production
triggered by OVA. Verapamil, a calcium channel antagonist, had similar anti-allergic properties, and curine pre-
treatment inhibited the calcium-induced tracheal contractile response ex-vivo, suggesting that the mechanism
bywhich curine exerts its effects is through the inhibition of a calcium-dependent response. A toxicological eval-
uation showed that orally administered curine did not signiﬁcantly alter the biochemical, hematological, behav-
ioral and physical parameters measured in the experimental animals compared with saline-treated animals. In
conclusion, curine showed anti-allergic activity throughmechanisms that involve inhibition of IL-13 and eotaxin
and of Ca++ inﬂux, without inducing evident toxicity and as such, has the potential for the development of anti-
asthmatic drugs.
© 2013 Elsevier Inc. All rights reserved.Introduction
Allergic asthma is an important public health problem in terms of
prevalence, morbidity and mortality, affecting approximately 20% of
the world's population and requiring costly therapy (Chatila, 2004;
Edwards et al., 2009). The pathophysiology of asthma is complex and
results from an inappropriate immune response to common allergens;
this response is characterized by chronic airway inﬂammation that is as-
sociatedwith intense leukocyte recruitment and activation at the site of
injury and airway hyper-responsiveness (AHR) (Barnes, 2008; Paul and
Zhu, 2010).
The current standard for the treatment of asthma involves the use of
drugs that relieve and control the symptoms of the disease (Holgate andzam), pbozza@ioc.ﬁocruz.br
ghts reserved.Polosa, 2008). Themedications that are broadly used in asthmamanage-
ment today include potent inhaled corticosteroids, such as budesonide
and ﬂuticasone; long-acting β2-adrenergic agonists (LABAs), such as
salmeterol and formoterol; and leukotriene modiﬁers, including
zaﬁrlukast, montelukast and zileuton; there are also combination thera-
pies that include inhaled corticosteroids and LABAs in a single delivery de-
vice (Szeﬂer, 2011). Corticosteroids are potent anti-inﬂammatory drugs
that regulate the expression of cytokines, chemokines and adhesionmol-
ecules by modulating the activity of transcription factors such as nuclear
factor-κB (NF-κB) and activator protein 1 (AP1). Inhaled corticosteroids
are very effective at inhibiting airway inﬂammation, and they represent
an important tool in asthmamanagement (Ivancsó et al., 2013). However,
these drugs are not effective under speciﬁc conditions, including virus- or
smoke-induced exacerbations (Harrison et al., 2004). β2-Adrenergic ago-
nists effectively promote bronchodilation through theproductionof cyclic
adenosine 3′5′-monophosphate (cAMP) and the activation of protein ki-
nase A (PKA). Inhaled short- and long-acting β2-adrenergic agonists are
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roids as a supplementary therapy for asthma (Holgate and Polosa,
2008). Phosphodiesterase inhibitors also increase cAMP, but these treat-
ments havebeen less commonlyused of late because of the low therapeu-
tic index of some drugs (Boswell-Smith et al., 2006). Antagonists of
cysteinyl leukotriene receptor 1 (CysLTR1) are currently available and
are important therapeutic tools in asthma. These drugs act by blocking
many activities of CysLTs, including bronchoconstriction, and are mainly
used as a supplementary therapy to inhaled corticosteroids (Polosa,
2007). Finally, mast cell inhibitors, cytokine-blocking monoclonal anti-
bodies and allergen-speciﬁc immunotherapies are also important in the
treatment of asthma and other allergic diseases (Edwards and Howell,
2000; Holgate and Polosa, 2008).
Despite the currently available array of anti-asthmatic therapies, the
search for structurally novel chemicals and for the development of safe
and effective drugs for the treatment of asthma and other allergic con-
ditions remains an important ﬁeld of investigation. Several studies
have shown that bisbenzylisoquinoline alkaloids (BBAs) have immuno-
modulatory activity against allergy and inﬂammation (Seow et al.,
1986; Teh et al., 1990). Our group has demonstrated that the alkaloid
warifteine has anti-allergic properties, including the inhibition of ana-
phylaxis, the inhibition of eosinophil recruitment and activation, the
ability to modulate airway hyper-responsiveness and remodelingCu
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Fig. 1. The effect of curine on eosinophil recruitment and activation. BALB/cmice (n = 5–7)we
asone (2 mg/Kg) 1 h before each challenge. Twenty-four hours after the last challenge, the BAL
A) the chemical structure of curine; B) the number of BAL eosinophils; C) the number of lipid
recruitment. These results are expressed as the mean ± SEM of at least 5 animals. + Signiﬁc
untreated, OVA-challenged group.(Bezerra-Santos et al., 2005, 2006, 2012) and the ability to inhibit hista-
mine release (Costa et al., 2008).
Curine (Fig. 1A) is a BBA that is themajor constituent of the root bark
of Chondrodendron platyphyllum (Menispermaceae). This compound
has a molecular structure that is similar to that of warifteine. Recently,
Medeiros et al. (2011) demonstrated that curinemay have direct effects
on L-type Ca2+ channels in vascular smoothmuscle cells. However, de-
spite curine's interesting pharmacological activity and its structural
similarity to warifteine, this molecule's anti-allergic properties and po-
tential for toxic effects remain to be investigated. Using a mouse
model of allergic asthma and ﬁnding no detectable toxicity, our study
is the ﬁrst to report that curine is beneﬁcial as an orally active anti-
allergic compound.
Methods
Curine puriﬁcation. C. platyphyllum Hil St. (Miers) was collected in the
municipality of Santa Rita, Paraíba, Brazil. The voucher specimen of
this plant is deposited in theHerbariumProf. Lauro PiresXavier, number
3631-P, and was identiﬁed by Prof. Dr Maria de Fatima Agra. Spectro-
scopically pure curinewas isolated from the root bark of C. platyphyllum
as described by Mambu et al. (2000). The curine solution was prepared
using 1 mgof the crystal in 50 μl of 1 NHCl and 500 μl of distilledwater.0 1 2 3 4 5
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re treated orally with increasing doses of curine (0.1, 0.5, 2.5 or 12.5 mg/Kg), or dexameth-
was collected and the eosinophils and lipid bodies were counted using a light microscope.
bodies per eosinophil; D) a dose–response curve of curine on the inhibition of eosinophil
antly different (p b 0.05) from the unchallenged group; * signiﬁcantly different from the
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to 1000 μl, and the dilutions were made in phosphate-buffered saline
(PBS).
Animals. Male BALB/c or Swiss mice weighing 20–30 g were obtained
from the Oswaldo Cruz Foundation breeding unit. The animals were
maintained with food and water ad libitum in a room with the temper-
ature ranging from 22 to 24 °C and a 12 h light/dark cycle. This study
was carried out in accordance with the recommendations of the
Brazilian National Council for the Control of Animal Experimentation
(CONCEA). The protocols were approved by the Animal Welfare
Committee of the Oswaldo Cruz Foundation (CEUA/FIOCRUZ protocol
# L-002/08).
Treatments. To perform the dose–response curve with eosinophil re-
cruitment as ameasured outcome, animals were treated orallywith dif-
ferent doses of curine (0.1, 0.5, 2.5 or 12.5 mg/Kg) or dexamethasone
(2 mg/Kg) orally (p.o.) 1 h before each challenge (pre-treatment
protocol). Alternatively, the mice were treated with curine (2.5 mg/Kg)
1 h after the last challenge (post-treatment protocol). The dose of curine
(2.5 mg/Kg) was chosen based on the results obtained from the pre-
treatment dose–response curve. Verapamil (2.5 mg/Kg) was given as a
control calcium channel antagonist. For the ex-vivo experiments, 9 μM
curine was used. This concentration was found to be the approximate
IC50 for the inhibition of calcium inﬂux in the experiments performed
by Medeiros et al. (2011). To evaluate the toxicological parameters, ani-
mals were treated orally once a day for 7 consecutive days with curine
(2.5 or 8 mg/Kg) or dexamethasone (2 mg/Kg). The control group
was treated orally with PBS. Importantly, the 8 mg/Kg dose of curine is
10-fold higher than its median effective dose (ED50).
Toxicological evaluation. The male Swiss mice were treated as described
above; their weight, behavior, and primary physical aspects (e.g., activity,
breath, piloerection, convulsions and diarrhea) were monitored daily.
Twenty-four hours after the last treatment, the animals were eutha-
nized by exposure to an atmosphere of CO2, and the blood was col-
lected by cardiac puncture. EDTA was added to the blood samples
for the hematological analyses of leukocytes, red blood cells (RBC),
platelets, hematocrit, hemoglobin, the mean corpuscular hemoglo-
bin concentration (MCHC), the mean corpuscular volume (MCV)
and the mean corpuscular hemoglobin (MCH). Blood samples were
centrifuged at 6000 g for 8 min at 4 °C to separate out the serum.
The serum concentrations of alkaline phosphatase, alanine transam-
inase (ALT), aspartate transaminase (AST), bilirubin, creatinine, cre-
atinine kinase, cholesterol, glucose, total proteins and uric acid were
determined. The relative weight and the macroscopic aspects of the
stomach, liver, spleen, thymus, intestines, kidneys and lungs were
analyzed, and the presence of gastric ulcer was assessed through
macroscopic and histological analyses.
Airway inﬂammation in actively sensitized mice. Allergic airway in-
ﬂammation was induced as described by Lloyd et al. (2001). The
animals were sensitized intraperitoneally (i.p.) with ovalbumin
(OVA — 10 μg/mouse) and Al(OH)3 (10 mg/mL) in a 0.9% NaCl
solution (saline 0.2 mL) on days 1 and 10. From day 19 to day 24
after sensitization, the mice were challenged daily for 20 min
with OVA (5%) in PBS by aerosol. Aerosolized PBS was administered
to some of the sensitized mice as a negative control. These proce-
dures were performed in a 30 × 20 × 10 cm acrylic chamber, and
the aerosol was generated by an ultrasonic nebulizer. Twenty-
four hours after the last challenge, the animals were euthanized
by exposure to an atmosphere of CO2, and the tracheawas surgically ex-
posed and cannulated. The bronchoalveolar lavage (BAL) was collected
from mice by washing the lungs with 1 mL of PBS.Leukocyte counts and lipid body enumeration. Total leukocyte counts
were performed using a Neubauer chamber under a light microscope
after diluting the BAL samples in Turk ﬂuid (2% acetic acid). Differential
counts were performed. To enumerate lipid bodies, the cells, while still
moist, were ﬁxed in 3.7% formaldehyde (diluted in Ca2+/Mg2+-free
HBSS; pH 7.4), rinsed in 0.1 M cacodylate buffer (pH 7.4), stained
with 1.5% OsO4 for 30 min, rinsed in distilled H2O, immersed in 1.0%
thiocarbohydrazide for 5 min, rinsed in 0.1 M cacodylate buffer,
restained with 1.5% OsO4 for 3 min, rinsed in distilled water and then
dried and mounted (Bozza et al., 1997). The cell morphology was
observed and the lipid bodies were enumerated by microscopy with
an objective lens at 100× magniﬁcation. Twenty-ﬁve consecutively
scanned eosinophils were evaluated, and the results were expressed
as the mean numbers of lipid bodies per eosinophil.
Cytokine quantiﬁcation. Twenty-four hours after the last challenge, the
lungs of the mice were surgically removed. Each lung was treated
with 800 μl of a complete cocktail solution of protease inhibitors
(Roche Diagnostics GmbH / Mannheim', Germany) containing both re-
versible and irreversible protease inhibitors and 20 μMEDTA. The cock-
tail solution was prepared by dissolving 1 tablet in 50 ml of 100 mM
phosphate buffer, pH 7.0. The lungs were then macerated, the samples
were centrifuged at 6000 g for 20 min at 4 °C, and the supernatants
were collected. The total protein concentration of these sampleswasde-
termined using a kit for the determination of proteins (BCA, fromPierce,
Rockford, IL). The concentrations of IL-13 and eotaxin were measured
using DuoSet kits according to the manufacturer's instructions (R&D
Systems).
Analysis of airway hyper-responsiveness. Airway hyper-responsiveness
(AHR) in the mice was analyzed using non-invasive whole body pleth-
ysmography (Buxco, Sharon, CT) 24 h after the last OVA challenge. AHR
was measured after the aerosolization of PBS followed by increasing
concentrations of methacholine (0, 6, 12.5 and 25 mg/mL; Sigma-
Aldrich), each of which was injected into the chamber for 2 min. The
AHR data were expressed as an average enhanced pause (Penh).
There was an interval of 10 min between each aerosol exposure, and
within this period of time, the Penh values had returned to baseline.
Analysis of the trachea contractile response ex vivo. Tissue preparation.
Male Wistar rats (8 weeks) were euthanized in a CO2 chamber; the
tracheas were removed and were immediately immersed in Krebs
nutritive solution (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM
MgSO4, 1.2 mMKH2PO4, 24 mMNaHCO3 and 11 mM glucose). The tra-
cheas were dissected and cut into segments of 3–4 rings. The segments
were mounted in isolated organ baths containing 10 mL of Krebs solu-
tion maintained at 37 °C and aerated with a carbogenic gas mixture
(95% O2 and 5% CO2). To achieve a constant level of spontaneous tone,
an initial tension of 1 g was applied. Contractions were measured iso-
metrically with a force-displacement transducer (Ugo Basile, Comerio,
Italy) and were recorded by an isolated organ data acquisition program
(Proto5; Letica Scientiﬁc Instruments, Barcelona, Spain).
Calcium-concentration response curve. Tissues were stabilized over a pe-
riod of 60 min; the bath solutionwas changed every 10 min. At the end
of the equilibration period, the response to carbachol (2.5 mM) was
recorded. After the removal of the carbachol and the restoration of the
tone to a stable baseline, the tissues were exposed to repeated cycles
of stimulation with 60 mM KCl and washing in a calcium-free Krebs
solution until there was complete desensitization of the contractile
response evoked by 60 mM KCl. Then, the tracheal segments were
immersed in Ca2+-free Krebs solution containing 60 mM KCl, and the
concentration of extracellular Ca2+ was gradually increased by the cu-
mulative addition of CaCl2 (0.01 to 100 mM) in the presence or absence
of 9 mM curine or vehicle. All of the responses were expressed as a per-
centage of the response to 2.5 mM carbachol (Foster et al., 1984).
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Tukey's test using GraphPad Prism software (GraphPad, San Diego, CA).
The values were expressed as the means ± S.E.M. Differences with
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Fig. 2. The effect of curine on airway hyper-responsiveness (AHR). OVA-sensitized
BALB/c mice (n = 7–8) were treated orally with curine (2.5 mg/Kg), or dexamethasone
(2 mg/Kg) 1 h before each challenge. AHR was analyzed by aerosolization with PBS
followed by increasing concentrations of methacholine, 24 h after the last allergicResults
Curine inhibits eosinophil recruitment and activation in a mouse model of
allergic asthma
An allergic challenge with OVA (5%) in actively sensitized mice in-
duced an intense inﬂux of eosinophils into the BAL that was associated
with the development of airway inﬂammation (Fig. 1B). To demon-
strate the anti-allergic effects of pre-treatment with curine, the animals
were pre-treated orally with curine (2.5 mg/Kg) or dexamethasone
(2 mg/Kg) 1 h before each OVA challenge. This treatment signiﬁcantly
reduced both the total number of eosinophils in the BAL (Fig. 1B) and
the numbers of cytoplasmic lipid bodies within those cells (Fig. 1C)
compared with the untreated OVA-challenged group. In this model,
curine had a dose-dependent effect, with a median effective dose
(ED50) of 0.8 mg/Kg (Fig. 1D).challenge. The AHR is expressed as the rate of enhanced pause (Penh). These results are
expressed as themean ± SEM.+Signiﬁcantly different (p b 0.05) from the unchallenged
group; * signiﬁcantly different from the OVA-challenged and untreated group.Curine decreases AHR in a mouse model of allergic asthma
Airway hyper-responsiveness is a hallmark of asthma. Fig. 2 shows
that an allergic challenge in actively sensitized BALB/c mice induced a
signiﬁcant increase in Penh values compared with the unchallenged
group. Daily pre-treatment with curine or dexamethasone (2 mg/Kg)
reduced the allergic reaction-triggered Penh values, indicating that
curine, similarly to dexamethasone, has an inhibitory effect on the de-
velopment of allergic AHR. Of note, when expressing data as % baseline
the results were the same (not shown). Importantly, curine failed to in-
hibit the methacholine response in the non-allergic vehicle group (not
show), demonstrating that curine does not alter the bronchoconstriction
induced by methacholine in the absence of inﬂammation.Curine inhibits the production of eotaxin and IL-13 in vivo
Eotaxin and IL-13 play key roles in allergic responses, including the
regulation of eosinophil migration and activation and the development
of AHR (Lloyd et al., 2001). As shown in Fig. 3, the BAL ﬂuid of actively
sensitized OVA-challenged mice contained increased concentrations of
these cytokines when compared with unstimulated mice. As shown in
Figs. 3A and B, curine and dexamethasone pre-treatments both de-
creased the eotaxin (Fig. 3A) and IL-13 (Fig. 3B) BAL concentrations
observed in the untreated OVA-challenged group, revealing a part of
the mechanism by which curine inhibits eosinophil recruitment and
activation and AHR.Effects of curine on the calcium-induced tracheal contractile response
Previous studies have shown that curine has an inhibitory effect
on calcium inﬂux in different cell types (Dias et al., 2002; Medeiros
et al., 2011). Therefore, we investigated the involvement of calcium-
dependent mechanisms on the anti-allergic effects of curine. In the ex-
periments with trachea ring preparations maintained in Ca2+-free me-
dium and depolarizedwith 60 mMKCl, the cumulative addition of Ca2+
(0.01 to 100 mM) produced a concentration-dependent contraction
that was inhibited by up to 50% by pre-treatment with 9 μM curine
(Fig. 4). This observation suggests that curine inhibits the inﬂux of
calcium by blocking the voltage-dependent Ca2+ channels in rat
tracheal smooth muscle and is consistent with previously published
data (Medeiros et al., 2011).Comparison between the anti-allergic effects of curine and verapamil
In recent work, Khakzad et al. (2012) demonstrated the anti-
inﬂammatory activity of verapamil, a calcium channel antagonist,
using a model of allergic asthma. To conﬁrm the role of calcium inﬂux
inhibition as an anti-allergic mechanism, we compared the effect of
verapamil to that of curine on AHR and eosinophil recruitment, two im-
portant features of asthma. When administered under the same condi-
tions (dose, time and pathway), verapamil and curine showed similar
anti-allergic effects (Fig. 5), suggesting that the anti-allergic effects of
curine may be due, at least in part, to the inhibition of calcium inﬂux.
Curine post-treatment inhibits eosinophil recruitment and activation in
OVA-challenged mice
To investigate the therapeutic effects of curine on ongoing airway
inﬂammation, we administered a single dose of curine 1 h after the
last allergic challenge (post-treatment). Balb/c mice post-treated with
curine had a reduced number of eosinophils (Fig. 6A) and similarly re-
duced numbers of eosinophil lipid bodies (Fig. 6B) in the BAL compared
with mice in the untreated group. Even when the treatment was given
after the development of inﬂammation, curine inhibited eosinophil
recruitment and activation; such ﬁndings demonstrate the therapeutic
effectiveness and the clinical relevance of curine.
Curine fails to induce toxic effects in orally treated mice
Outbred Swiss mice treated orally with curine daily for seven days
were evaluated for toxicological parameters. Outbred mouse stocks
were used for the toxicological evaluation because of their genetic het-
erogeneity and their common use in toxicological studies (Faqi, 2012).
We found that curine treatment did not induce signiﬁcant alterations in
biochemical (Table 1), hematological (Supplement Table S1) or physical
and behavioral parameters and in gastric ulcer formation (Supplement
Table S2) compared with saline treatment, even at a dose of 8 mg/Kg
(a dose 10 times higher than the ED50). These data indicate that curine
is able to inhibit allergic inﬂammation at doses at which it does not in-
duce signiﬁcant toxicity. On the other hand, dexamethasone treatment
induced an increase in the concentrations of total proteins, cholesterol
and ALT compared with saline treatment, reﬂecting the side effects
broadly described in the literature. Of note, no alterations in physical
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Fig. 3.The effect of curine on eotaxin and IL-13 production. BALB/cmice (n = 5–6) primedwithOVAwere treated orallywith curine (2.5 mg/Kg), or dexamethasone (2 mg/Kg) 1 h before
each challenge. Twenty-four hours after the last challenge, the lungs were collected and homogenized. The production of eotaxin (A) was analyzed using an EIA protocol, and the produc-
tion of IL-13 (B) was analyzed by ELISA. These results are expressed as the mean ± SEM from at least 6 animals. + Signiﬁcantly different (p b 0.05) from the unchallenged group; * sig-
niﬁcantly different from the OVA-challenged and untreated group.
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Balb/c mice treated with curine at 2.5 mg/kg (not shown).
Discussion
Allergic diseases, including asthma, have multifactorial etiologies,
and their prevalence, morbidity and mortality have been increasing
around the world (Edwards et al., 2009). Asthma is usually treated
with a combination of anti-inﬂammatory and bronchodilator drugs.
Inhaled corticosteroids are currently the most important drugs used to
control airway inﬂammation. Because of their potent inhibitory effects
on cell activation, cytokine and lipid mediator production and adhesion
molecule and inﬂammatory receptor expression, they are simulta-
neously able to block several essential steps of the inﬂammatory-3 -2 -1 0 1 2 3
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Fig. 4. The effects of curine on the calcium-induced tracheal contractile response.
A contractile response was triggered after the cumulative application of calcium in
tracheal segments maintained in Krebs solution rich in K+ (60 mM) and free of calcium.
Pre-treatment with curine (9 μM) led to a decrease in tension after the addition of
calcium. Each point represents the mean ± S.E.M. from at least six segments. The
magnitude of the voltage induced contraction of trachea calcium preparations was
expressed as a percentage of the contractile response evoked by 2.5 mM carbachol.
* Signiﬁcantly different from the vehicle.cascade (Barnes, 2006, 2011; Barnes and Adcock, 2009; Rhen and
Cidlowski, 2005). However, corticosteroid therapy induces important
side effects (Schacke et al., 2004), and somepatients are completely cor-
ticoid resistant or fail to show clinical improvement after treatment
with high doses of oral glucocorticoids (Barnes et al., 1995). This situa-
tion can limit the use of corticosteroids and impairs the patients' life
quality. Some reports suggest that the ineffectiveness of corticosteroids
in some severe forms of asthma is due to their failure to decrease the
level of TH1 cytokines, such as tumor-necrosis factor (TNF) (Truyen
et al., 2006). Classic bronchodilator drugs including β2-adrenergic ago-
nists and phosphodiesterase inhibitors have long been used to control
the shortness of breath that is characteristic of asthmatic attacks; how-
ever, these drugs are also not free from side effects (Boswell-Smith et al.,
2006). Currently, leukotriene antagonists have been employed suc-
cessfully in asthma therapy. Nevertheless, they are not effective as
a monotherapy and are therefore mainly used as a supplementary
therapy to inhaled corticosteroids (Polosa, 2007). Mast cell inhibitors,
monoclonal antibodies, 5-lipoxygenase inhibitors and allergen-speciﬁc
immunotherapy have also found a place in asthma therapy (Edwards
and Howell, 2000; Holgate and Polosa, 2008). However, novel, safe
and effective drugs are needed for the treatment of asthma, and the
assessment of new compounds with potentially unique mechanisms
of action remains an important area of research.
In this work, we have for the ﬁrst time demonstrated the anti-
allergic properties and toxicological characterization of curine, an orally
active bisbenzylisoquinoline alkaloid. To investigate the anti-allergic
properties of curine,we used awell-establishedmousemodel of asthma
induced by allergic sensitization and challenge with OVA. Eosinophilic
inﬁltration into the airways is a hallmark of this model; allergic chal-
lenge induces eosinophil maturation and differentiation from precur-
sors in the bone marrow and their migration to sites of inﬂammation
in response tomediators such as eotaxin and IL-5 (Gleich, 2000). There-
fore, we performed a dose–response experiment with oral treatment
with curine, and we observed that such treatment dose-dependently
inhibited the number of eosinophils in the BAL, supporting the inhib-
itory role that curine plays in eosinophil recruitment.
To further understand the additional effects of curine, we analyzed
the formation of lipid bodies in eosinophils. Increased lipid body assem-
bly within eosinophils is closely associated with cellular activation and
LTC4 production in an allergic response and therefore plays important
roles in inﬂammatory conditions and may be used as a marker of
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Fig. 5. A comparison between the anti-allergic effects of curine and verapamil. BALB/c mice (n = 6–8) primed with OVA were treated orally with curine (2.5 mg/kg) or verapamil
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et al., 2005). We demonstrated not only that the animals treated with
curine showed a reduced number of eosinophils in the BA but also
that these eosinophils had fewer cytoplasmic lipid bodies, indicating
that curine plays an inhibitory role on both migration and activation
of these cells. Our group has demonstrated that the inhibition of lipid
bodies is an important parameter that can be used to evaluate the
anti-inﬂammatory effects of drugs; furthermore, evaluating the inhibi-
tion of lipid bodies may be useful in understanding the pharmacology
and therapeutic efﬁcacy of new interventions in numerous conditions
such as asthma, allergies, cancer, atherosclerosis, diabetes and other dis-
eases inwhich the formation of lipid bodies is a negative clinical param-
eter (Bozza et al., 2009).Weobserved that treatmentwith curine aswell
as dexamethasone signiﬁcantly reduced the production of eotaxin in
the model we used. It has been shown that eotaxin plays a key role in
eosinophil migration and activation (Vieira-de-Abreu et al., 2005),Cu
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Fig. 6. The effect of post-treatment curine on eosinophil recruitment and activation. OVA-sensit
allergic challenge. Dexamethasone (2 mg/Kg) was administered 1 h before each challenge wi
bodies (B) were counted using a light microscope. These results are expressed as the mean ±
different from the OVA-challenged and untreated group.which supports the effects of curine described herein. AHR is a particu-
lar feature of asthma, resulting from complex interactions between
inﬂammatory and airway smooth muscle (ASM) cells, leading to recur-
rent episodes of shortness of breath, wheezing and coughing (Lauzon
et al., 2012). Here, we showed that curine has an important inhibitory
activity on AHR, decreasing the observed Penh values to levels similar
to those observed in the animals treated with dexamethasone. To eluci-
date the mechanisms involved in the anti-allergic effects of curine, we
analyzed the production of key mediators of allergic responses, such
as IL-13. Previous studies have demonstrated that blocking IL-13 in
mice prevents the development of AHR (Wills-Karp et al., 1998).
Furthermore, Kuperman et al. (2005, 2002) demonstrated that the
overexpression of IL-13 in mice was sufﬁcient to cause AHR, possibly
through a direct effect on the airway epithelium. Importantly, IL-13 is
also involved in the modulation of various pathophysiological aspects of
asthma, such as class switching to IgE, mucus production, inﬂammation,Cu
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Table 1
The biochemical analyses of serum frommale Swiss mice treated with curine (2.5 or 8 mg/kg) or dexamethasone (2 mg/kg) for 7 days.
Parameter (unit) Vehicle Curine (2.5 mg/kg) Curine (8 mg/kg) Dexamethasone
(2 mg/kg)
Alkaline Phosphatase 222.40 ± 22.70 212.20 ± 32.80 218.90 ± 19.45 284.20 ± 38.13
ALT 79.50 ± 15.37 62.80 ± 4.25 82.67 ± 12.37 101.30 ±13.37
AST 98.83 ± 15.91 94.10 ± 8.76 112.10 ± 11.17 175.10 ± 25.44⁎
Bilirubin 0.64 ± 0.03 0.67 ± 0.04 0.81 ± 0.04 1.15 ± 0.09⁎
Creatinine 0.20 ± 0.00 0.22 ± 0.01 0.22 ± 0.02 0.20 ± 0.00
Creatinine Kinase 289.00 ± 90.75 261.60 ± 60.55 267.40 ± 41.97 227.90 ± 26.16
Cholesterol 62. 29 ± 2.50 65.67 ± 3.90 63.60 ± 4.52 106.60 ± 10.30⁎
Glucose 264.00 ± 25.26 249.60 ± 18.47 297.50 ± 15.29 292.80 ± 72.41
Total Proteins 5.29 ± 0.09 5.42 ± 0.08 5.54 ± 0.10 7.27 ± 0.17⁎
Uric acid 3.73 ± 0.47 3.90 ± 0.54 5.03 ± 0.42 2.90 ± 0.79
These values are expressed as the mean ± S.E.M. AST = aspartate transaminase. ALT = alanine transaminase.
⁎ Signiﬁcantly different from the vehicle group (p b 0.05).
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with speciﬁc receptors on the cell surface (Bloemen et al., 2007).
Allergicmechanisms involve signaling and the activation ofmany cell
types, including leukocytes and epithelial and airway muscle cells
(Paul and Zhu, 2010). Eosinophilic inﬂammation and AHR are important
features of asthma, and both processes require calcium-dependent
mechanisms. Accordingly, recent work has demonstrated that verapa-
mil, a calcium channel antagonist, signiﬁcantly inhibited goblet cell hy-
perplasia,mucus hypersecretion and inﬂammation in amodel of allergic
asthma (Khakzad et al., 2012).Medeiros et al. (2011) demonstrated that
curine might have a direct effect on L-type Ca2+ channels in vascular
smooth muscle cells. In this work, we investigated the involvement of
calcium-dependent mechanisms on the anti-allergic effects of curine.
We demonstrated that curine pre-treatment signiﬁcantly inhibited a
calcium-induced trachea contractile response ex vivo, suggesting that
curine inhibits the inﬂux of calcium by blocking voltage-dependent
Ca2+ channels in rat tracheal smooth muscle. Interestingly, in non-
allergic mice, curine did not alter the bronchoconstriction induced by
methacholine (in vivo), which is mediated by calcium release from in-
tracellular stores (Foster et al., 1984). These data support our hypothesis
that curine inhibits calciumchannels in the cellmembrane. Additionally,
in vivo treatments with curine or verapamil (an L-type calcium-channel
antagonist) using the same dose, time and method of administration
had similar effects on AHR and eosinophilic inﬂammation, suggesting
that the anti-allergic effects of curinemay be, at least in part, dependent
on the inhibition of calcium inﬂux. Indeed, calcium-dependent signaling
plays key roles both in asthma-related cytokine production and in their
function. Antigen-triggered cytokine and chemokine expression is
largely dependent on the activation of NFAT, a transcription factor that
requires Ca2+ for its activation (Macian, 2005). Rothenberg et al.
(1996) demonstrated that eotaxin signaling through its receptor,
CCR3, effectively induced a calcium inﬂux into eosinophils in vitro. Addi-
tionally, Moynihan et al. (2008) demonstrated that IL-13 modulated
AHR by inducing SOCS expression and a calcium inﬂux into human
airway smooth muscle cells.
Finally, we investigated the possible toxicity of curine by oral treat-
ment because this parameter has not previously been addressed exper-
imentally. To that end, Swiss mice were treated daily for seven days
with curine at doses of 2.5 and 8 mg/Kg. The dose of 2.5 mg/Kgwas cho-
sen because it had a signiﬁcant anti-allergic effect throughout the ex-
periments and the dose of 8 mg/Kg is 10 fold higher than the ED50.
We also included a group treated with dexamethasone (2 mg/Kg, p.o.)
here as we did for other experiments. All of the treatments were com-
pared with the oral treatment with PBS with HCl and NaOH added
(pH 7), which was used as a vehicle for the dilution of the curine. The
toxicological evaluation showed that the treatmentwith curine induced
no changes in the hematologic or biochemical parameters. Additionally,
the treatment did not induce the formation of gastric ulcers, and there
were no physical or behavioral changes, indicating that under these
conditions, curine showed no evident toxicity.Aiming to provide additional therapeutic information concerning
the anti-allergic properties of curine, we have demonstrated that curine
post-treatment was effective in the inhibition of eosinophil recruitment
and activation; this observation highlights the potential of curine as an
anti-allergic compound, as post-treatment more accurately replicates
what happens in clinical situations.
In conclusion, orally administered curine showed potent anti-
allergic activity without inducing evident toxicity and, as such, has the
potential for the development of anti-asthmatic drugs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2013.08.015.
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